You are here:Home
»
Antibodies
»
Abs to Growth Factors, Cytokines
»
Anti -Bone Morphogenetic Protein 9 (BMP9, Growth and Differentiation Factor 2, GDF2)
Anti -Bone Morphogenetic Protein 9 (BMP9, Growth and Differentiation Factor 2, GDF2)
Pricing
For pricing information, USA customers sign in. Outside USA? Please contact your distributor for pricing. Specifications
| Clone |
Host |
Grade |
Applications |
| Polyclonal |
Goat |
Affinity Purified |
E B |
|
| Human BMP9 is a member of the BMP subgroup of the TGF-beta superfamily proteins that signal through heterodimeric complexes composed of type I and type II BMP receptors. BMP9 regulates the development and function of a variety of embryonal and adult tissues. The human BMP9 cDNA encodes a 429 amino acid (aa) precursor that includes a 22aa signal sequence, a 298aa propeptide, and a 111aa mature protein. Unlike with other BMP family proteins, the propeptide does not interfere with the biological activity of BMP9 and remains associated with the mature peptide after proteolytic cleavage. Human and mouse BMP9 share 96% aa sequence identity. Within the mature protein, human BMP9 shares 64% aa sequence identity with human BMP10 and less than 50% aa sequence identity with other BMPs. BMP9 is expressed by non-parenchymal cells in the liver, where it promotes lipid metabolism and inhibits glucose production. BMP9 exerts a prolonged hypoglycemic effect which may be due to an enhancement of insulin release. BMP9 interacts with a high affinity specific heteromeric receptor expressed on liver endothelial cells that has been identified as ALK-1. In the embryonal CNS, BMP9 functions in the development and maintenance of the cholinergic neuronal phenotype. BMP9 also induces the differentiation of mesenchymal stem cells into the chondrogenic lineage. At low concentrations, BMP9 is a proliferative factor for hematopoietic progenitor cells, but at higher concentrations, it enhances TGF-beta1 production and inhibits hematopoietic progenitor colony formation. | | | Applications: | | | Suitable for use in Western Blot and Direct ELISA. Other applications not tested. | | | Recommended Dilutions: | | | Western Blot: 0.1-0.2ug/ml. The detection limit for recombinant human BMP9 Propeptide is ~1ng/lane under non-reducing and reducing conditions. | | | Direct ELISA: 0.5-1.0ug/ml. The detection limit for recombinant human BMP9 Propeptide is ~0.3ng/well. | | | Optimal dilutions should be determined by each laboratory for each application. | | | Storage and Stability: | | | Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile PBS. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. | | | Catalog # | B2553-36B | | Clone Type | Polyclonal | | Isotype | IgG | | Host | Goat | | Source | Human | | Concentration | ~0.2mg/ml (after reconstitution) | | Form | Supplied as a lyophilized powder from PBS, 5% trehalose. Reconstitute with 500ul sterile PBS. | | Purity | Purified by immunoaffinity chromatography. | | Immunogen | Recombinant corresponding to aa23-319 from human Bone Morphogenetic Protein 9 (BMP9) Propeptide expressed in CHO cells. | | Specificity | Recognizes human BMP9 Propeptide. In direct ELISAs and Western Blots, shows <1% crossreactivity with mature recombinant human BMP9. | | | Important Note | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. |
External Links
|
